XANTUS: Rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation

Vascular Health and Risk Management

Volumn 10, Issue , 2014, Pages 425-434

  Camm, A John ^a   Amarenco, Pierre ^b   Haas, Sylvia ^c   Hess, Susanne ^d   Kirchhof, Paulus ^e,f   van Eickels, Martin ^d   Turpie, Alexander G G ^g  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b SORBONNE UNIVERSITÉ   (France)

^c Vascular Centre   (Germany)

^d BAYER PHARMA AG   (Germany)

^e SANDWELL AND WEST BIRMINGHAM HOSPITALS NHS TRUST   (United Kingdom)

^f UNIVERSITY OF MÜNSTER   (Germany)

^g MCMASTER UNIVERSITY   (Canada)

Author keywords

Anticoagulants; Atrial fibrillation; Phase IV; Rivaroxaban; Stroke

Indexed keywords

RIVAROXABAN; WARFARIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; OBSERVATIONAL STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PROSPECTIVE STUDY; STUDY DESIGN; AFRICA; ATRIAL FIBRILLATION; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPLICATION; EUROPE; METHODOLOGY; MIDDLE EAST; MULTICENTER STUDY; PHASE 4 CLINICAL TRIAL; RISK ASSESSMENT; RISK FACTOR; SAMPLE SIZE; SOUTH AND CENTRAL AMERICA; STROKE; TIME; TREATMENT OUTCOME;

AFRICA; ATRIAL FIBRILLATION; CLINICAL PROTOCOLS; EUROPE; FACTOR XA INHIBITORS; HUMANS; LATIN AMERICA; MIDDLE EAST; MORPHOLINES; PROSPECTIVE STUDIES; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; SAMPLE SIZE; STROKE; THIOPHENES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84904643420     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S63298     Document Type: Article

References (24)

1. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis,9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest.2012;141(Suppl 2):e531S-e575S.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke.1991;22(8): 983-988.
3. Nieuwlaat R, Olsson SB, Lip GY, et al. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. Am Heart J.2007;153(6): 1006-1012.
4. Ansell J, Hollowell J, Pengo V, Martinez-Brotons F, Caro J, Drouet L. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). J Thromb Thrombolysis.2007;23(2):83-91.
5. Camm AJ, Lip GY, De Caterina R, et al.2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J.2012;33(21):2719-2747.
6. Furie KL, Goldstein LB, Albers GW, et al. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke.2012;43(12): 3442-3453.
7. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med.2011;365(10): 883-891.
8. Janssen Pharmaceuticals. Xarelto (rivaroxaban) [prescribing Information].2013. Available from: http://www.accessdata.fda.gov/ drugsatfda_docs/label/2013/202439s008lbl.pdf. Accessed January27, 2014.
9. Bayer Pharma. Xarelto (rivaroxaban) [summar y of product characteristics].2013. Available from: http://www.ema.europa. eu/docs/en_GB/document_library/EPAR_-_Product_Information/ human/000944/WC500057108.pdf. Accessed April23,2014.
10. Mueck W, Becka M, Kubitza D, Voith B, Zuehlsdorf M. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in healthy subjects. Int J Clin Pharmacol Ther.2007;45(6):335-344.
11. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY59-7939-an oral, direct factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol.2005;61(12):873-880.
12. Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov.2011;10(1):61-75.
13. Buller HR, Lensing AW, Prins MH, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood. 2008;112(6):2242-2247.
14. Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with Acute Symptomatic Deep-Vein Thrombosis) study. Circulation.2007;116(2):180-187.
15. Mueck W, Lensing AW, Agnelli G, Décousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet. 2011;50(10):675-686.
16. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study. Am Heart J.2010;159(3): 340-347.
17. Wong KS, Hu DY, Oomman A, et al. Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial. Stroke. Epub April24, 2014.
18. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864-2870.
19. Lip GYH, Nieuwlaat R, Pisters R, Lane D, Crijns H. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: the Euro Heart Survey on Atrial Fibrillation. Chest.2010;137(2):263-272.
20. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-1100.
21. Turpie AG, Schmidt AC, Kreutz R, et al. Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery. Vasc Health Risk Manag.2012;8:363-370.
22. Turpie AG, Haas S, Kreutz R, et al. A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in17,701 patients with propensity score adjustment. Thromb Haemost.2014;111(1):94-102.
23. Kakkar AK, Mueller I, Bassand JP, et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J. 2012;163(1):13-19.
24. Piccini JP, Fraulo ES, Ansell JE, et al. Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J.2011;162(4):606-612.